Want to see ALDX full AI Analyst Report?
Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target
ALDX Analyst Ratings
ALDX Stock 12 Month Forecast
Average Price Target
$2.00▲(215.96% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Matthew Caufield | H.C. Wainwright | $2 | hold | 215.96%Upside | Reiterated | 09/30/26 | ||
| Thomas Shrader | BTIG | $9 | buy | 1321.80%Upside | Reiterated | 03/17/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Matthew CaufieldH.C. Wainwright | HoldReiterated$2 | 09/30/26 | 215.96%Upside | ||
| Thomas ShraderBTIG | BuyReiterated$9 | 03/17/26 | 1321.80%Upside |
Best Analysts Covering Aldeyra Therapeutics
Copying Thomas Shrader's trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +11.57% per trade.
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +0.20% per trade.
Copying Thomas Shrader's trades and holding each position for 2 Years would result in 20.83% of your transactions generating a profit, with an average return of -35.08% per trade.
ALDX Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 3 | 3 | 2 |
In the current month, ALDX has received 0 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ALDX average Analyst price target in the past 3 months is 2.00.
ALDX Financial Forecast
ALDX Earnings Forecast
Next quarter’s earnings estimate for ALDX is -$0.09 with a range of ― to ―. The previous quarter’s EPS was -$0.09. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
ALDX Sales Forecast
Next quarter’s sales forecast for ALDX is $0 with a range of ― to ―. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
